Mechelen, Belgium; 19 December 2011 – Galapagos NV (Euronext: GLPG) announced today that investigational medicine GLPG0778, which is part of its immuno-inflammatory alliance with GlaxoSmithKline, has shown selective effects on a biomarker in a Phase I Proof-of-Mechanism study in healthy volunteers. The study also provided information on the safety and pharmacokinetic (PK) profile of GLPG0778.
Ardea Biosciences, Inc. RDEA -1.58% today announced that it has initiated the first of four planned Phase 3 clinical trials in its development program for lesinurad, the Company’s lead product candidate for the chronic treatment of gout. The lesinurad Phase 3 development program is expected to involve approximately 2,000 gout patients at sites around the world. The remaining Phase 3 studies in the program are expected to begin shortly.
19 December 2011, Starpharma (ASX: SPL; OTCQX SPHRY) today announced the advancement of its drug delivery collaboration with US pharmaceutical corporation Eli Lilly and Company.
NewGen Therapeutics Inc. said Monday it has acquired three oncology development programs from Kanion USA Inc. in Hayward and and Kanion Pharmaceutical Co. Ltd. in Lianyungang, China.
Diseases such as cancer or Alzheimer’s can disrupt the energy-producing pathways inside cells. To help spot these shifts, researchers have developed a small molecule that allows them to use magnetic resonance techniques to monitor metabolism in animals (J. Am. Chem. Soc., DOI: 10.1021/ja2040865). They hope that the probe someday could help researchers and doctors study and diagnose disease.
Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (prebabalin) Capsules CV In Restless Legs Syndrome
Pfizer Inc. PFE -0.10% announced today that a Phase 3 study for Lyrica (pregabalin) in patients with Restless Legs Syndrome (RLS) met each of its three co-primary endpoints, showing significant benefit as compared with placebo and pramipexole. Pfizer will continue to further analyze these top-line results.
The addition of the small molecule vorinostat (Zolinza) to bortezomib (Velcade) therapy for multiple myeloma patients appears to show a modest but statistically significant improvement in progression-free survival (PFS) when compared with placebo, researchers reported here.
Leave it to engineers to come up with a potentially novel solution to fight Alzheimer’s disease. Scientists at Rensselaer Polytechnic Institute led by Peter Tessier, an assistant professor of chemical and biological engineering, have designed antibodies that neutralize the amyloid protein that leads to Alzheimer’s disease. Yes, this is early stage research, and the finding is a long road from the lab to treatment in people. Also, RPI points out that brain tissue is very well protected, and a hard place in which to successfully deliver drug treatments.
Ipsen plans to expand its commitment, investment and commercial presence in the U.S. market through a series of moves. The company will make a multi-million dollar capital investment in its Milford, MA R&D and technical operations facility, and will relocate U.S. Operations headquarters from Brisbane, CA, to Bridgewater, NJ, in order to enhance the North American commercial organization.
Bristol-Myers Squibb Company and Simcere Pharmaceutical Group today announced an expanded strategic partnership to include a second collaboration on a cardiovascular compound.